Stifel Nicolaus Sticks to Its Buy Rating for Evolus (EOLS)
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Evolus (EOLS – Research Report) today and set a price target of $25.00.
Janux Therapeutics Inc (JANX) Receives a Buy from BTIG
In a report released today, Justin Zelin from BTIG maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report), with a ...
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...